VS-7375/GFH375

DRUG3 trials

Sponsors

Verastem Inc.

Conditions

Advanced KRAS G12D-Mutant Solid TumorsMetastatic KRAS G12D-Mutated Colorectal AdenocarcinomaNon-Small Cell Lung Cancer

Phase 1

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

Not yet recruitingCTIS2025-523432-39-01

Verastem Inc.Advanced KRAS G12D-Mutant Solid Tumors

Target: 120Updated: 2026-06-10

Phase 2

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Not yet recruitingCTIS2026-526473-42-00

Verastem Inc.Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma

Target: 15Updated: 2026-10-21

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

Not yet recruitingCTIS2026-526472-23-00

Verastem Inc.Non-Small Cell Lung Cancer

Target: 13Updated: 2026-10-27